Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of BI 1839100 in Healthy Japanese Males
NCT05934955Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jul 2023
- Primary completion
- Sep 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of BI 1839100 in idiopathic pulmonary fibrosis (IPF) and chronic cough (4 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Occurrence of any treatment-emergent adverse event assessed as drug-related by the investigator up to 10 days. Started Jul 2023; status: completed.
02
Drugs
BI 1839100
03
Conditions
idiopathic pulmonary fibrosis (IPF)chronic cough
Beyond the preview
Go deeper on NCT05934955.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05934955.